Search results
Showing 1 to 13 of 13 results for selpercatinib
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development [GID-TA11160] Expected publication date: TBC
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
In development [GID-TA11289] Expected publication date: TBC
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
This guidance has been updated and replaced by NICE technology appraisal guidance 1038.
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
This guidance has been updated and replaced by NICE technology appraisal guidance TA1042
In development [GID-TA11301] Expected publication date: TBC